Key result
No clinical study data is present in the provided text, which consists only of journal masthead and publication information.
Why the study?
Does argatroban differ from recombinant hirudin in its effect on tissue-factor-mediated thrombin generation in human plasma?
Does argatroban differ from recombinant hirudin in its effect on tissue-factor-mediated thrombin generation in human plasma?
In vitro, argatroban and recombinant hirudin exhibit distinct effects on thrombin generation, reflecting their reversible and irreversible binding mechanisms, respectively.
No takes yet. Share an insight, caveat, or question.
No clinical data guide argatroban versus hirudin selection; leaves open whether in vitro thrombin-generation differences affect patient outcomes.
Samama et al. (2008) studied this question. No clinical study data is present in the provided text, which consists only of journal masthead and publication information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: